Novartis to present 46 MS abstracts; stock after-hours at EUR 128.88, plus 3.43 percent
Published on 10/07/2026 at 18:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
In a release dated October 7, 2026, Novartis said it will present 46 abstracts from its multiple sclerosis portfolio at MSToronto2026. The stock was at EUR 128.88 after-hours at 5:54 p.m. CEST, according to Lang & Schwarz, up EUR 4.27, or plus 3.43 percent, versus the EUR 124.61 prior close.
After-hours trading
Lang & Schwarz showed a bid of EUR 128.84 and an ask of EUR 128.92 on October 7, 2026. The price reference was the prior close of EUR 124.61 at Lang & Schwarz. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.
Multiple sclerosis program
The company said a late-breaking abstract will feature results from the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib, an oral BTK inhibitor, in relapsing multiple sclerosis. Novartis also plans a late-breaking presentation of Phase III NEOS data on Kesimpta, or ofatumumab, in pediatric multiple sclerosis. These details were reported in the GlobeNewswire release.
Presentations scheduled for October
Additional scheduled material includes STHENOS results on ofatumumab versus physicians’ choice of disease-modifying therapy in treatment-naive people with relapsing multiple sclerosis. The release also lists KATHAROS interim results on ofatumumab excretion in breast milk and pregnancy and infant outcomes from the PRIM study. Novartis said it will hold a virtual investor call following presentation of the REMODEL data. The presentation details are provided in the company announcement.
